Electra Therapeutics is a clinical-stage biotechnology company developing first-in-class antibody therapeutics targeting signal regulatory proteins (SIRPs) for the treatment of immunological diseases and cancer. The company was launched in 2018 as the first spinout of Star Therapeutics' hub-and-spoke biotech platform and is headquartered in South San Francisco, California. Its lead candidate, ELA026, is a monoclonal antibody designed to selectively deplete pathological myeloid cells and T lymphocytes via SIRP targeting, currently in pivotal-stage development as a frontline treatment for secondary hemophagocytic lymphohistiocytosis (sHLH). A Phase 1b study reported 100% overall survival at 8 weeks in malignancy-associated HLH patients, versus ~50% historical benchmarks. A second pipeline program, ELA822, is advancing toward clinical development for broader immunology and inflammation indications. Electra has raised over $267 million in disclosed equity financing across Series B and Series C rounds, with backing from leading life sciences investors including Nextech, EQT Life Sciences, Westlake Village BioPartners, OrbiMed, Sanofi, Mubadala Capital, and HBM Healthcare Investments.
Electra Therapeutics is publicly traded
This company is no longer available on our private secondary market. Shares can be traded publicly under its listed ticker.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2018
Employees
11–50
Total Funding
$267M
3 rounds
Began trading on Nasdaq as ETRA after pricing an upsized $350M IPO at $15 per share; closed first day at $13.25
Now a listed company; ~$941M market cap at the IPO price
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $267M across 3 rounds
Last updated 10-07-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| Oct 22, 2025 | Series C | $183M | — | Nextech Invest, EQT Life Sciences |
| Feb 16, 2022 | Series B | $84M | — | Westlake Village BioPartners, OrbiMed |
| 2018 | Series A | — | — | Star Therapeutics |
Kathy Dong
President and Chief Executive Officer
Graham Parry
Chief Scientific Officer
Kim-Hien Dao
Chief Medical Officer
Adam Rosenthal
Co-Founder and Board Director (CEO, Star Therapeutics)
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Sobi (Swedish Orphan Biovitrum)
Marketer of Gamifant (emapalumab), the only currently FDA-approved therapy for primary HLH and a competitor in the HLH treatment landscape that Electra's ELA026 is targeting.
ALX Oncology
Clinical-stage immuno-oncology company developing CD47/SIRP-alpha blockade therapeutics (evorpacept); competes broadly in the SIRP-targeted antibody therapeutics space, though with a different mechanism (checkpoint blockade vs. cell depletion).
Pfizer (Trillium Therapeutics)
Through its 2021 acquisition of Trillium, Pfizer holds SIRP-alpha-targeting molecules (TTI-621, TTI-622) for hematologic malignancies, overlapping with Electra's SIRP-targeted oncology pipeline.
Gilead Sciences (Forty Seven)
Owns magrolimab (anti-CD47, the SIRP-alpha ligand) via its $4.9B acquisition of Forty Seven; a major incumbent in CD47/SIRP-axis therapeutics for hematologic malignancies and solid tumors.
Sana Biotechnology
Develops engineered cell therapies and uses SIRP-alpha-Fc fusion ('hypoimmune') technology to evade immune rejection of allogeneic cells; an adjacent player in the SIRP biology landscape with different therapeutic applications.
Electra Therapeutics priced an upsized initial public offering of 23,333,334 shares at $15.00 on September 17, 2026, raising approximately $350 million in gross proceeds, and began trading on the Nasdaq Global Select Market under the ticker ETRA on September 18, 2026. The shares closed their first day at $13.25. Proceeds are earmarked mainly for the registrational Phase 2/3 program of ipsoprubart (ELA026) in secondary HLH.
Electra Therapeutics shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker to place an order.
Electra Therapeutics raised $267M across 3 disclosed funding rounds prior to its public listing.
Electra Therapeutics was founded by Adam Rosenthal in 2018.
Electra Therapeutics is headquartered in South San Francisco, CA, USA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.